EGFR and lung adenocarcinoma: For example, ZD1839 (gefitinib) as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor was superior to the first-line carboplatin–paclitaxel regimen in East Asian patients with lung adenocarcinoma who were non-smokers or former light smokers (hazard ratio for progression or death, 0.74) and more favorable for patients with EGFR gene mutation subgroup (hazard ratio for progression or death, 0.48) (18).